Liquid Biopsy Market Set to Grow at 23.4% CAGR (2017 to 2021) - Projected to Reach US$ 1.66 Billion - Top Key Players,Overview, Regional Forecast, Analysis, Growth Projection and Shares

#Download Free Sample Papers of Liquid Biopsy Market spread across 160 Pages, Profiling 11 Companies and Supported with 75 Tables and 74 Figures is now available at https://www.reportsnreports.com/contacts/requestsample.aspx?name=631133 .

The liquid biopsy market is expected to reach USD 1.66 Billion by 2021 from USD 0.58 Billion in 2017, growing at a CAGR of 23.4% during forecast period of 2017 to 2021. Technological advancements, increasing number of new cancer cases, availability of funding, growing awareness about liquid biopsy through conferences and government initiatives, and benefits of liquid biopsy over solid tumor biopsy are some of major factors driving growth of market.

Key players operating in liquid biopsy market are Biocept Inc. (U.S.), Myriad Genetics (U.S.), QIAGEN (Netherlands), Roche (Switzerland), Bio-Rad Laboratories Inc. (U.S.), Trovagene Inc. (U.S.), Guardant Health, Inc. (U.S.), Janssen Diagnostics, LLC (U.S.), Fraunhofer-Gesellschaft (Germany), and MDxHealth SA (U.S.).

Liquid biopsy market classified into hospital/physician laboratories, reference laboratories, academic and research centers and other end users. Other end-users segment includes public health laboratories, pathology laboratories, and small molecular laboratories. Detailed insights on upcoming technologies, research & development activities, and new product launches in liquid biopsy market.

Key Audience of This Market as Follows:
• Pharmaceutical Companies
• Biotechnology Companies
• Research Institutes
• Contract Research Organizations
• Research and Consulting Companies
• Liquid Biopsy Product Manufacturers and Distributors
• Hospitals and Diagnostics Centers
• Reference Laboratories
• Government and Public Laboratories

#Click Here For More Information Now at
https://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=631133 .

The liquid biopsy market is segmented based on cancer type, circulating biomarkers, products & services, end users, and regions. Based on cancer type, the market is segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, liver cancer, and other cancers (melanoma, bladder cancer, and ovarian cancer).

Based on cancer type, liquid biopsy market segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, liver cancer, and other cancers (melanoma, bladder cancer, and ovarian cancer). Based on circulating biomarkers, the liquid biopsy market is segmented into circulating tumor DNA (ct DNA), circulating tumor cells (CTCs), extracellular vesicles (EVs), and other biomarkers (circulating RNA and protein).

Premium Insights
1 Liquid Biopsy: Market Overview
2 Geographic Analysis: Liquid Biopsy Market, By Circulating Biomarker
3 Market Size, By End User,
4 Market Size, By Product,
5 Market Size, By Circulating Biomarker,
6 Geographical Snapshot of the Market

#Corporate Discount on this study “Liquid Biopsy Market by Cancer Type (Lung, Breast, Colorectal, Prostate, Liver), Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA), Product (Instruments, Software), End User (Reference Laboratory, Research Centers) - Forecast to 2021” report at http://www.reportsnreports.com/contacts/discount.aspx?name=631133 .

The report analyzes the liquid biopsy market and aims at estimating market size and future growth potential of this market based on various segments such as by product, circulating biomarker, clinical application, application, end user, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1– 15%, Tier 2– 45%, and Tier 3–40%
• By Designation– C-level– 27%, Director Level–33%, Others–40%
• By Region – North America–25%, Europe–45%, Asia-Pacific–15%, RoW–15%

Geographical , the global liquid biopsy market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. In 2022, North America is expected to dominate the market which can be attributed to the easy accessibility and high adoption of advanced diagnostic technologies (such as PCR and NGS) among healthcare professionals. The APAC region is expected to register the highest CAGR during the forecast period.

ReportsnReports is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.

Corporate Headquarters
Tower B5, office 101,
Magarpatta SEZ,
Hadapsar, Pune-411013, India
+ 1 888 391 5441
sales@reportsandreports.com

This release was published on openPR.